Malaria medicines: a glass half full?
Related Experiment Video
Updated: Apr 12, 2026

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
Published on: July 11, 2025
Timothy N C Wells1, Rob Hooft van Huijsduijnen1, Wesley C Van Voorhis2
1Medicines for Malaria Venture, 20 Route de Pré-Bois, 1215 Geneva 15, Switzerland.
Abstract:
Despite substantial scientific progress over the past two decades, malaria remains a worldwide burden that causes hundreds of thousands of deaths every year. New, affordable and safe drugs are required to overcome increasing resistance against artemisinin-based treatments, treat vulnerable populations, interrupt the parasite life cycle by blocking transmission to the vectors, prevent infection and target malaria species that transiently remain dormant in the liver. In this Review, we discuss how the antimalarial drug discovery pipeline has changed over the past 10 years, grouped by the various target compound or product profiles, to assess progress and gaps, and to recommend priorities.
More Related Videos
10:22Methods to Investigate the Regulatory Role of Small RNAs and Ribosomal Occupancy of Plasmodium falciparum
Published on: December 4, 2015
09:13Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
Published on: November 22, 2024
Related Concept Videos
Anthelminthic Agents
Symbiosis
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Diversity of Protists II
Cholinergic Antagonists: Pharmacokinetics
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms: